Loading organizations...
§ Private Profile · CALLE ORENSE 58 28020, MADRID, Madrid Spain
Veritas Intercontinental is a technology company.
Veritas Intercontinental is a genetic testing company that provides comprehensive genomic analysis services, primarily focusing on whole genome and exome sequencing. The company utilizes advanced technology, including machine learning and artificial intelligence, to interpret extensive genetic information, offering insights for preventive medicine, perinatal care, and diagnostic genomics. These services aim to transform complex genetic data into clinically relevant information for improved health outcomes.
Veritas Intercontinental was established in 2018 to spearhead the global expansion of the Veritas brand and its genetic services across Europe, Latin America, the Middle East, and Japan. The original Veritas was co-founded by Dr. George Church, a pioneering geneticist known for his work on the Human Genome Project, alongside a team of scientists from Harvard Medical School’s Personal Genome Project. Their foundational insight centered on making the benefits of genomic data widely accessible to individuals.
The company’s products serve individuals seeking proactive, personalized health information and medical professionals who require genetic diagnostic tools for patients with various health conditions or family histories. Veritas Intercontinental’s mission is to convert genetic data into actionable insights, ultimately enhancing the quality and longevity of human life. It continuously refines its offerings as global genetic knowledge advances, committing to ongoing innovation in genomic analysis.
Veritas Intercontinental has raised $31.9M across 3 funding rounds.
Veritas Intercontinental has raised $31.9M in total across 3 funding rounds.
Veritas Intercontinental has raised $31.9M in total across 3 funding rounds.
Veritas Intercontinental's investors include Andrea Traversone, Francisco G. Churtichaga, Graham Snudden, Stemar Capital Partners, Amadeus Capital Partners.
Veritas Intercontinental has raised $31.9M across 3 funding rounds. Most recently, it raised $5.9M Series B in October 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 15, 2020 | $5.9M Series B | Andrea Traversone, Francisco G. Churtichaga | Graham Snudden, Stemar Capital Partners | Announced |
| Jul 1, 2020 | $6M Series A | — | Amadeus Capital Partners | Announced |
| Jul 1, 2018 | $20M Series A | — | Amadeus Capital Partners | Announced |
Veritas Intercontinental is a genomics company that provides genetic testing services, including whole genome sequencing, exome-based tests like myGenome, and counseling to prevent diseases and improve health outcomes.[1][2][3] Founded in 2018 and headquartered in Madrid, Spain, it expanded Veritas Genetics' brand into Europe, Latin America, the Middle East, and Japan, serving consumers and healthcare providers with AI-driven genomic interpretation.[1][2][3] It offered services such as maternal-fetal medicine testing through its European lab opened in 2020, but was acquired by LetsGetChecked in March 2022, enhancing at-home personalized healthcare.[1][2][3]
The company targeted individuals seeking preventive health insights via scalable genome analysis, addressing challenges in genetic data accessibility amid declining sequencing costs and rising demand for targeted therapies.[2][3]
Veritas Intercontinental traces its roots to Veritas Genetics, co-founded by Harvard geneticist George Church and leaders from Harvard Medical School’s Personal Genome Project, inspired by Church's 1970s DNA research that contributed to the Human Genome Project.[1][2] The core vision was to democratize genomic data for global health benefits, evolving with AI and machine learning for everyday integration.[1][2]
Founded in 2018, Veritas Intercontinental specifically drove international expansion, establishing a state-of-the-art lab in Spain in 2020 using Illumina technology for end-to-end testing.[2][3] Early traction included a full portfolio rollout and $5.85M in funding before its 2022 acquisition by LetsGetChecked, marking a pivotal shift to broader healthcare solutions.[1][2][3]
Veritas Intercontinental rode the genomics boom fueled by plummeting sequencing prices, expanding genetic knowledge, and demand for targeted therapies amid improved data management.[3] Its timing aligned with post-Human Genome Project advancements, enabling consumer-accessible testing in high-growth regions like Europe and Latin America.[1][2][3]
Market forces such as rising NGS (next-generation sequencing) adoption in hospitals, newborn screening, and inherited disorder detection favored its model, with North America leading revenue but Asia-Pacific accelerating.[3] By integrating AI for genomic insights, it influenced personalized medicine ecosystems, paving the way for at-home health via its LetsGetChecked acquisition.[1][3]
Post-2022 acquisition, Veritas Intercontinental's platform bolsters LetsGetChecked's at-home genomics, likely expanding AI-driven whole-genome services globally.[1][3] Trends like precision medicine growth, regulatory support for consumer genetics, and AI scalability will shape its trajectory, potentially amplifying influence in preventive care ecosystems.[2][3]
As genomics integrates deeper into daily health, its Church-founded legacy positions it to redefine personalized healthcare, fulfilling the Human Genome Project's promise for millions.